Contineum Therapeutics, Class Stock Net Income
| CTNM Stock | 12.68 0.37 3.01% |
Fundamental analysis of Contineum Therapeutics, allows traders to better anticipate movements in Contineum Therapeutics,'s stock price by examining its financial health and performance throughout various phases of its business cycle.
| Last Reported | Projected for Next Year | ||
| Net Loss | -42.3 M | -40.1 M | |
| Net Loss | -42.3 M | -40.1 M | |
| Net Loss | (2.18) | (2.07) | |
| Net Income Per E B T | 0.88 | 0.78 |
Contineum | Net Income | Build AI portfolio with Contineum Stock |
Contineum Therapeutics, Class Company Net Income Analysis
Contineum Therapeutics,'s Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Contineum Therapeutics, Net Income | (42.26 M) |
Most of Contineum Therapeutics,'s fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Contineum Therapeutics, Class is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Contineum Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Contineum Therapeutics, is extremely important. It helps to project a fair market value of Contineum Stock properly, considering its historical fundamentals such as Net Income. Since Contineum Therapeutics,'s main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Contineum Therapeutics,'s historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Contineum Therapeutics,'s interrelated accounts and indicators.
Click cells to compare fundamentals
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Contineum Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Contineum Therapeutics, Class reported net income of (42.26 Million). This is 112.38% lower than that of the Pharmaceuticals sector and 160.33% lower than that of the Health Care industry. The net income for all United States stocks is 107.4% higher than that of the company.
Contineum Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Contineum Therapeutics,'s direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Contineum Therapeutics, could also be used in its relative valuation, which is a method of valuing Contineum Therapeutics, by comparing valuation metrics of similar companies.Contineum Therapeutics, is currently under evaluation in net income category among its peers.
Contineum Therapeutics, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Contineum Therapeutics,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Contineum Therapeutics,'s managers, analysts, and investors.Environmental | Governance | Social |
Contineum Fundamentals
| Return On Equity | -0.3 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | 286.28 M | ||||
| Shares Outstanding | 30.45 M | ||||
| Shares Owned By Insiders | 1.14 % | ||||
| Shares Owned By Institutions | 58.34 % | ||||
| Number Of Shares Shorted | 1.7 M | ||||
| Price To Book | 2.57 X | ||||
| Price To Sales | 11.15 X | ||||
| EBITDA | (42 M) | ||||
| Net Income | (42.26 M) | ||||
| Total Debt | 6.26 M | ||||
| Book Value Per Share | 6.18 X | ||||
| Cash Flow From Operations | (32.84 M) | ||||
| Short Ratio | 6.43 X | ||||
| Earnings Per Share | (2.25) X | ||||
| Target Price | 22.04 | ||||
| Number Of Employees | 41 | ||||
| Market Capitalization | 463.19 M | ||||
| Total Asset | 212.85 M | ||||
| Retained Earnings | (117.4 M) | ||||
| Working Capital | 196.41 M | ||||
| Net Asset | 212.85 M |
About Contineum Therapeutics, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Contineum Therapeutics, Class's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Contineum Therapeutics, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Contineum Therapeutics, Class based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetCheck out Contineum Therapeutics, Piotroski F Score and Contineum Therapeutics, Altman Z Score analysis. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Contineum Therapeutics,. If investors know Contineum will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Contineum Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Contineum Therapeutics, is measured differently than its book value, which is the value of Contineum that is recorded on the company's balance sheet. Investors also form their own opinion of Contineum Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Contineum Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Contineum Therapeutics,'s market value can be influenced by many factors that don't directly affect Contineum Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Contineum Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Contineum Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Contineum Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.